bluebird bio (BLUE) : 10 Wall Street analysts covering bluebird bio (BLUE) believe that the average level the stock could reach for the short term is $78.5. The maximum price target given is $117 and the minimum target for short term is around $42, hence the standard deviation is calculated at $25.04.
bluebird bio (BLUE) : 12 analysts are covering bluebird bio (BLUE) and their average rating on the stock is 1.5, which is read as a Strong Buy. 9 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Also, Cantor Fitzgerald initiates coverage on bluebird bio (NASDAQ:BLUE).The analysts at the brokerage house have a current rating of Hold on the shares. In a recent information released to the investors, Cantor Fitzgerald announces the price target of $42 per share. The rating by the firm was issued on June 2, 2016.
bluebird bio (NASDAQ:BLUE): The stock opened at $49.50 on Thursday but the bulls could not build on the opening and the stock topped out at $50.19 for the day. The stock traded down to $48.67 during the day, due to lack of any buying support eventually closed down at $49.33 with a loss of -0.02% for the day. The stock had closed at $49.34 on the previous day. The total traded volume was 595,771 shares.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.